OBJECTIVE: The expression of fatty acid synthase (FAS), an enzyme necessary for de novo fatty acid synthesis, has been examined in several types of tumours so far, but not in oesophageal cancer and dysplasia. METHODS: We examined the immunohistochemical reactivity of FAS in 4 normal adult oesophagi, 14 dysplastic oesophageal lesions, and 80 squamous cell carcinomas and 6 cases with 4 special types of malignancies of the oesophagus. We also analysed the correlation between FAS expression and various clinicopathological features and long-term survival in patients with oesophageal cancer. RESULTS: In the normal oesophagus, only faint cytoplasmic FAS expression was observed in cells of the basal layer. In contrast, FAS-positive cells were found in 92.9% of cases of dysplasia and 96.5% of cases of carcinoma including 6 cases with a specific histological subtype. However, high expression of FAS did not correlate with either clinicopathological features or prognosis of patients with oesophageal cancer. CONCLUSION: Our results demonstrate that FAS is expressed in almost all oesophageal carcinomas of both usual and special types and dysplastic lesions, suggesting that FAS may be upregulated continuously from the early stage of oesophageal squamous cell carcinogenesis to established carcinoma. Copyright 2002 S. Karger AG, Basel
OBJECTIVE: The expression of fatty acid synthase (FAS), an enzyme necessary for de novo fatty acid synthesis, has been examined in several types of tumours so far, but not in oesophageal cancer and dysplasia. METHODS: We examined the immunohistochemical reactivity of FAS in 4 normal adult oesophagi, 14 dysplastic oesophageal lesions, and 80 squamous cell carcinomas and 6 cases with 4 special types of malignancies of the oesophagus. We also analysed the correlation between FAS expression and various clinicopathological features and long-term survival in patients with oesophageal cancer. RESULTS: In the normal oesophagus, only faint cytoplasmic FAS expression was observed in cells of the basal layer. In contrast, FAS-positive cells were found in 92.9% of cases of dysplasia and 96.5% of cases of carcinoma including 6 cases with a specific histological subtype. However, high expression of FAS did not correlate with either clinicopathological features or prognosis of patients with oesophageal cancer. CONCLUSION: Our results demonstrate that FAS is expressed in almost all oesophageal carcinomas of both usual and special types and dysplastic lesions, suggesting that FAS may be upregulated continuously from the early stage of oesophageal squamous cell carcinogenesis to established carcinoma. Copyright 2002 S. Karger AG, Basel
Authors: Loretha Carlisle-Moore; Chris R Gordon; Carl A Machutta; W Todd Miller; Peter J Tonge Journal: J Biol Chem Date: 2005-10-07 Impact factor: 5.157
Authors: Pietro Crispino; Piero Luigi Alò; Margherita Rivera; Domenica Barillà; Francesco Nardi; Mauro Mariotti; Zotti Giancarlo; Claudio Botti; Roberta Pica; Claudio Cassieri; Hans Unim; Paolo Paoluzi Journal: J Cancer Res Clin Oncol Date: 2009-05-27 Impact factor: 4.553
Authors: Camila Matsunaga de Angelis; Reydson Alcides de Lima-Souza; João Figueira Scarini; Erika Said Abu Egal; Gleyson Kleber do Amaral-Silva; Rogério de Oliveira Gondak; Oslei Paes de Almeida; Carlos Takahiro Chone; Luiz Paulo Kowalski; Albina Altemani; Fernanda Viviane Mariano Journal: Head Neck Pathol Date: 2021-04-11
Authors: Franco A Rossato; Karina G Zecchin; Paolo G La Guardia; Rose M Ortega; Luciane C Alberici; Rute A P Costa; Rodrigo R Catharino; Edgard Graner; Roger F Castilho; Aníbal E Vercesi Journal: PLoS One Date: 2014-06-25 Impact factor: 3.240